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The effects of antiepileptic drugs, gabapentin, pregabalin and vigabatrin, on brain gamma-aminobutyric acid (GABA), glutamate
and glutamine concentrations were studied in Long Evans rats using proton magnetic resonance spectroscopy (MRS) of perchloric
acid extracts. Cellular glutamate concentrations significantly decreased by 7% (P < 0.05) 2 hours after intraperitoneal injection
of 100 mg/kg gabapentin and 4% (P < 0.05) with 1000 mg/kg. No differences were observed in cellular GABA and cellular
glutamine concentrations in rats treated with gabapentin. Pregabalin, an analogue of gabapentin, significantly decreased cellular
glutamate concentrations by 4% (P < 0.05), while no effect was observed on cellular GABA or glutamine concentrations in
the healthy rat forebrain. Vigabatrin, used as a positive control to increase GABA levels, produced a 50% increase in cellular
GABA compared to saline treated rats (P < 0.003). Although, gabapentin and pregabalin are anticonvulsants designed to mimic
GABA, these drugs do not raise cellular GABA levels acutely but modestly decreased cellular glutamate levels in our healthy
rat forebrain model.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
The majority of excitatory neurons in the human neo-
cortex release glutamate as their primary neurotrans-
mitter1. The glutamate content of brain primarily
reflects the glutamate concentration in glutamater-
gic neurons, whose glutamate content is far greater
than non-glutamatergic neurons or glia2, 3. Enhanced
glutamatergic activity is coupled tightly to increased
neuron-glia cycling and cerebral energy metabo-
lism4–7. Opposing the action of glutamate is GABA,
the major inhibitory neurotransmitter in the adult
human cortex1, 8. Because glutamate is its precursor,
GABA metabolism is coupled tightly to neuron-glia
cycling and cerebral energy metabolism9–12.
Gabapentin, pregabalin, and vigabatrin are three
new antiepileptic drugs (AEDs) originally designed
to target the GABAergic system13, 14. Vigabatrin is
a well-characterised vinyl analogue of GABA that
irreversibly inhibits GABA-transaminase resulting in
a significant increase in GABA levels in both human
and rodents15, 16. The first oral dose of vigabatrin
(50 mg/kg) doubles cellular GABA concentrations
within 2 hours when used by patients with refractory
localisation-related epilepsies17. Daily dosing appears
to increase cortical glutamine and lower glutamate
content17, 18. Gabapentin and pregabalin are lipophilic
analogues of GABA, whose anticonvulsant and anal-
gesic mechanisms of action remain unclear13, 19–21.
The first dose of gabapentin (20 mg/kg) increases cel-
lular GABA within 2 hours when given orally to hu-
man subjects22, 23. Limited studies measuring cortical
glutamate and glutamine in epilepsy patients taking
gabapentin daily suggest changes would be modest
at best12. Similar studies to determine the effects of
pregabalin on GABA levels in epilepsy patients have
yet to be reported.
In animal models, only a few studies have investi-
gated the effects of gabapentin on cortical amino acid
neurotransmitter levels. Gabapentin (5–75 mg/kg)
fails to increase forebrain GABA concentration24.
However, in the presence of a GABA catabolism
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inhibitor, gabapentin (23 mg/kg) administration re-
sults in regional increases in brain GABA synthesis25.
In addition, acute administration of gabapentin
(50 mg/kg) results in an increase in glutamine concen-
tration, whereas, chronic gabapentin administration
produces a decrease in glutamate24. To date, the role
of pregabalin on brain amino acid neurotransmitter
concentrations has yet to be examined fully.
Our study investigates the acute effects of gabapentin
and pregabalin on rat brain GABA, glutamate and glu-
tamine concentrations to further understand the mech-
anisms of these antiepileptic drugs. Vigabatrin serves
as a positive control because it reliably increases
cellular GABA levels in humans and rodents15, 16.
EXPERIMENTAL PROCEDURES
Animal protocol
Male Long Evans rats (Charles River, Wilming-
ton, MA, USA) weighing 190–220 g received an
intraperitoneal (i.p.) injection of either gabapentin,
pregabalin-active optical isomer, pregabalin-inactive
optical isomer (Parke-Davis, Ann Arbor, MI, USA),
vigabatrin (500 mg/kg; n = 8) or vehicle (n = 56;
physiological saline, Butler, Columbus, OH, USA).
Gabapentin was administered at 100 mg/kg (n = 10)
and 1000 mg/kg (n = 16). Pregabalin has two chiral
isomers; only one optical isomer has anticonvulsant
properties (pregabalin-active). Pregabalin-active was
given at 50 mg/kg (n = 12), 250 mg/kg (n = 12) and
500 mg/kg (n = 8). Pregabalin-inactive was given at
50 mg/kg (n = 12) and 250 mg/kg (n = 12). At the
time of the injections, the experimenters did not know
which enantiomer was biologically active. Vigabatrin,
a well-characterised GABA-transaminase inhibitor,
was used as a positive control to increase cellular
GABA15, 16.
Post injection, animals had free access to food
and water. Two hours after drug administration, an-
imals received an i.p. injection of 100 mg/kg pento-
barbital followed by an i.p. injection of 0.4 ml 2N
3-mercaptopropionic acid (3-MPA; Sigma Chem-
icals, St. Louis, MO, USA). Four minutes after
3-MPA injection26, 27, animals were decapitated and
brains were quickly removed (<90 seconds) ros-
tral to the cerebellum and frozen in liquid nitrogen.
Blood was collected after decapitation from rats that
received 1000 mg/kg gabapentin rats (n = 8) and
500 mg/kg pregabalin (n = 8). The 2-hour time pe-
riod was chosen based on the observation that maxi-
mal gabapentin concentrations in brain were achieved
within 1 hour and maximal protection from elec-
troshock seizures occurred 2 hours following admin-
istration of gabapentin28, 29. The Yale Animal Care
and Use Committee approved the protocol. Rats were
purchased through and maintained by Yale Animal
Resource Centre.
Extraction method
Frozen brains were extracted in 3.5 ml cold 12% per-
chloric acid (PCA) stock solution containing 7.7 mM
dichloracetic acid (Sigma Chemicals) and centrifuged
at 3200 × g for 15 minutes at 4 ◦C. The supernatant
was brought to a neutral pH with a solution containing
4.8 M KOH and 0.3 M K2HPO4 and centrifuged at
3200× g for 10 minutes at 4 ◦C. The neutral solution
was treated with 0.5 g chelating resin (Sigma Chem-
icals), filtered, and lyophilised. The dried powder
was dissolved in neutral 50 mM deuterated phosphate
in D2O containing 2 mM isopropanol as previously
described30. Dichloracetic acid was added to the ex-
traction procedure as a concentration standard and
chemical shift reference. Blood specimens were ex-
tracted as above with 1:1 ratio of blood to PCA
solution.
Spectroscopy and data analysis
High resolution proton magnetic resonance spec-
troscopy (MRS) was performed on a Brucker
AM-500 (Billerica, MA, USA) analytical spectrom-
eter at 500 MHz and 22 ◦C using a 30◦ pulse width
(5 microseconds), 6024 Hz sweep width, 32K digital
resolution, and low power presaturation. NUTS 1D
(Acorn NMK Inc., Fremont, CA, USA) was used to
process and measure proton MR spectra. Fig. 1 shows
representative proton MR spectra of extracted from
forebrains of rats treated with gabapentin, pregabalin,
vigabatrin, and saline. Metabolite concentrations in an
individual animal were determined using the creatine
signal at 3.0 ppm that was assigned the average abso-
lute value of total creatine (creatine plus phosphocre-
atine) measured for all animals (12.2 mM). Student
t-test was used to determine significant differences
with Bonferroni correction for multiple comparisons
when needed.
RESULTS
Cellular glutamate concentrations decreased sig-
nificantly (P < 0.005) in gabapentin-treated rats
(Table 1) and this decrease was significant (P <
0.05) at both doses of gabapentin. Overall, the
pregabalin-active group showed a 4% decrease (P <
0.05) of cellular glutamate concentration compared
to pregabalin-inactive treated animals. Compared to
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Fig. 1: Representative proton MR spectra of extract from forebrains of rats treated with gabapentin (1000 mg/kg), pregabalin
(500 mg/kg), vigabatrin (500 mg/kg) and saline highlight the ability of MRS to measure the forebrain concentrations of
antiepileptic drugs. The concentration of gabapentin in brain extracts (0.7 mM; SEM, 0.2) was 70% of the levels found in blood
(0.9 mM; SEM, 0.2). In contrast only 30% of the pregabalin levels measured in the blood (0.90 mM; SEM, 0.04) were
observed in the brain (0.34 mM; SEM, 0.02). NAA: N-acetylaspartate; Gln: glutamine; Glt: glutamate; GABA:
gamma-aminobutyric acid; gpn: gabapentin; pgn: pregabalin.
Table 1: Acute effects of gabapentin, pregabalin and vigabatrin on GABA, glutamate and glutamine concentrations in the rat
brain.
GABA Glutamate Glutamine
Saline control (n = 56) 2.36 ± 0.03 13.1 ± 0.1 3.7 ± 0.1
Vigabatrin (n = 8) 3.51 ± 0.18* 12.6 ± 0.4 3.6 ± 0.2
Gabapentin (n = 26) 2.42 ± 0.03 12.4 ± 0.2* 3.6 ± 0.1
Pregabalin-active (n = 32) 2.41 ± 0.04 12.5 ± 0.2* 3.6 ± 0.1
Pregabalin-inactive (n = 24) 2.37 ± 0.03 13.1 ± 0.2 3.7 ± 0.1
Values represent the mean concentrations (mM) with± SEM.
* P < 0.05 versus saline control using the Student t-test.
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Fig. 2: Comparison of acute antiepileptic drug (AED) treatment to percent difference of glutamate concentrations when
compared to controls.
saline treated controls, the pregabalin-active group
showed a significant decrease (P < 0.05, corrected
for a three-way comparison) in cellular glutamate
levels (Table 1). The level of significance at individ-
ual dosages for rats treated with 50 and 250 mg/kg
pregabalin-active showed a similar decrease in cellu-
lar glutamate levels when compared to saline controls
(Fig. 2). None of the AEDs examined had any sig-
nificant effect on cellular glutamine levels measured
when compared to saline treated rats (Table 1).
Gabapentin and pregabalin, at low and high doses,
failed to increase cellular GABA concentration in rat
forebrain after acute drug treatment, whereas, the con-
trol AED, vigabatrin showed a 45% increase in GABA
(Table 1).
DISCUSSION
Gabapentin administration results in a significant
though modest decrease in forebrain cellular glu-
tamate levels in our model, without significant
changes in cellular GABA or glutamine content. A
ten-fold increase in dose did not magnify the ef-
fect. Gabapentin crosses the blood–brain barrier by
a transporter-mediated mechanism that appears to
be saturated at a dose of 100 mg/kg31. Forebrain
gabapentin content (0.7 mM; SEM, 0.2) achieves
70% of the concentration in the blood, measured
2 hours after intraperitoneal injection of 1000 mg/kg;
a dose that should saturate gabapentin transport. At
this concentration, gabapentin would be expected
to inhibit the system-L branched-chain-amino acid
(BCAA) transporter (Ki, 0.03–0.18 mM) competi-
tively and enhance GABA release through reversal of
the GABA-uptake transporters (0.05–0.1 mM)32–34.
Gabapentin modulates activities of enzymes and
transporters that affect glutamate metabolism de-
creasing glutamate and glutamine content in several
model systems35–38. Glutamatergic neurotransmis-
sion is highly dependent on the net synthesis of
glutamate by neurons3, 6. Neurotransmitter release of
glutamate results in the obligate loss of tricarboxylic
acid (TCA) cycle intermediates because neurons lack
sufficient enzymatic capacity to resynthesise gluta-
mate lost through neurotransmission from glucose
without depleting mitochondrial stores of TCA cycle
intermediates7, 12, 39. A large fraction of the gluta-
mate released by neurons is taken up by surrounding
astrocytes and converted to glutamine, which is re-
leased by system-L and system-N transporters40.
Transported into neurons by system-A and system-L,
glutamine is deaminated by phosphate activated glu-
taminase, which serves as the main neuronal enzyme
for the net synthesis of glutamate7, 12, 41. The com-
plete pathway is called the glutamine–glutamate
cycle (Fig. 3). Anaesthesia with chloralose or
pentobarbital-coma slows the glutamine–glutamate
cycle significantly and decreases cortical glutamate
content by 16–28%42.
The glutamine–glutamate cycle is coupled tightly
with ammonia detoxification43, 44. Neuronal gluta-
mate dehydrogenase (GDH) can detoxify ammonia
by combining it with alpha-ketoglutarate (-KG), a
critical TCA cycle intermediate, to form glutamate.
The branched-chain-amino-acid cycle ferries the am-
monia from neurons to glia in a non-toxic form and
regenerates -KG, avoiding depletion of neuronal
TCA cycle intermediates36, 38, 45. Interfering with the
uptake of leucine has a major impact on ammonia
detoxification and would be expected to lower cellular
glutamate concentrations (Fig. 3).
Gabapentin can modulate ammonia handling, and
thus, affect the glutamine–glutamate cycle in several
ways21, 32, 35, 38, 46. It is a competitive inhibitor of
system-L (leucine) transporters, thereby decreasing
the branched-chain-amino-acid content of astrocytes
and potentially glial glutamate needed for efficient
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Fig. 3: Schematic of the glutamine–glutamate cycle and branched-chain-amino-acid cycle. In order to detoxify ammonia (NH3)
entering the brain from the blood, glia synthesise glutamate de novo from glucose using pyruvate carboxylase (PC), the TCA
cycle, and the mitochondrial form of branched-chain-amino-acid transaminase (BCAA-T). Ammonia entering from the blood or
released by cerebral metabolism is detoxified by glutamine synthetase (GS). Astrocytes release glutamine into the blood or
extracellular space using primarily system-N, but also system-L (SLT), transporters. Neurons take up glutamine by the
system-A (SAT) transporter and SLT systems to replace glutamate lost through glutamatergic neurotransmission
(glutamine–glutamate cycle), GABA synthesis, or oxidation. The mitochondrial enzyme, phosphate activated glutaminase
(PAG), converts glutamine to glutamate and ammonia. Ammonia strongly inhibits PAG, thereby decreasing neuronal glutamate
synthesis. Ammonia released by neuronal metabolism can diffuse into the glia to be detoxified by GS. Alternatively, neuronal
GDH can detoxify ammonia by combining it with -KG to form additional glutamate at the expense of depleting neuronal TCA
cycle intermediates. The branched-chain-amino-acid cycle ferries the ammonia from neurons to glia in a non-toxic form and
regenerates -KG, avoiding depletion of neuronal TCA cycle intermediates. Gabapentin slows the branched-chain-amino-acid
cycle by inhibiting both the neuronal form of BCAA-T and SLT, responsible for the neuronal release of leucine and valine and
their glial uptake. Gabapentin appears to activate GDH, both to detoxify and release ammonia, which would make the
equilibrium more dependent on the availability of -KG. Low levels of -KG would lead to increasing neuronal ammonia levels
and inhibition of PAG, thereby decreasing neuronal glutamate concentrations.
ammonia detoxification44. Similarly, gabapentin
would disrupt the branched-chain-amino-acid cycle
between neurons and glia by inhibiting transporter
mediated leucine release from neurons and astrocytic
uptake (Fig. 3). Gabapentin appears to affect glu-
tamine transport, promoting the release of glutamine
from astrocytes35. In neurons, it could potentially
slow glutamine uptake.
At the brain concentrations (0.7 mM with 1000
mg/kg) achieved in our model, gabapentin would be
expected to inhibit the neuronal form of branched-
chain-amino-acid transaminase (BCAA-T; Ki 0.8 mM
for leucine, 0.7 mM for ketoisovalerate), further
disrupting the branched-chain-amino-acid cycle35.
Gabapentin significantly impairs glutamate and glu-
tamine synthesis in a perfused rat retina model at
concentrations of 0.2–1.0 mM, thereby decreasing
glutamate content36–38. The largest impact was on the
de novo synthesis of glutamate from glucose through
the anaplerotic (pyruvate carboxylase) pathway.
Gabapentin has no significant effect on glutamine
synthetase47 or glutaminase48. We observe a min-
imal decrease in glutamine (0.1 mM, ∼3%) that
failed to reach the 0.05 level of statistical signifi-
cance. At higher concentrations, gabapentin inhibits
GABA degradation by GABA-transaminase (Ki,
17–20 mM) and stimulates glutamic acid decarboxy-
lase (at 1–3 mM)25, 48–50. A minor increase in cellular
GABA (0.06 mM, ∼3%) is observed, but failed to
reach significance.
Pregabalin is the isobutyl analogue of gabapentin
designed to circumvent in part the limitations in ab-
sorption and transport that appear to limit the bioavail-
ability of gabapentin13, 19, 50, 51. Administration of
pregabalin-active, the enantiomer with antiepileptic
properties, results in a significant though very mod-
est decrease (0.6 mM, ∼4%) in forebrain cellular
glutamate levels. The pregabalin enantiomer lacking
antiepileptic activity has no apparent effect. At the
forebrain concentrations (0.34 mM with 500 mg/kg)
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achieved in our study, pregabalin-active would be
expected to affect potassium-evoked glutamate re-
lease, which is decreased by 11–26% in hippocampal
and neocortical slices with the application of 0.1 mM
pregabalin-active52. Pregabalin-active is reported to
be a weaker inhibitor of BCAA-T (Ki, 0.84) than
gabapentin and would not be expected to have sig-
nificant effects at concentrations achieved in our
animals50. Acute administration of pregabalin-active
(2.5 mM) enhances GAD activity by 43% in a con-
centration dependent manner that could lead to the
increase production of GABA resulting in the anticon-
vulsant effect observed in animal models51. As with
gabapentin, pregabalin-active appears to be associated
with a minimal (0.1 mM,∼4%) decrease in glutamine.
There is no change in glutamine with pregabalin-
inactive. In our model, pregabalin does not increase
cellular GABA content significantly (pregabalin-
active increases GABA by 2% and pregabalin-inactive
has no effect). Recently, Whitworth and Quick report
that pregabalin, like gabapentin, promotes GABA
release through reversal of the GABA-transporter
(GAT1) at concentrations (25–100µM) grossly
exceeded in our animals34. Overall, the effects
of pregabalin-active appear similar to those of
gabapentin, whereas values of animals treated with
pregabalin-inactive are identical to saline controls.
CONCLUSION
Gabapentin and the isoform of pregabalin with
antiepileptic effects significantly decreased cellular
glutamate by 0.6–0.9 mM (4–7%) in healthy rat fore-
brain. Whether the decrease in glutamate content is
proconvulsant or anticonvulsant appears to depends
on conditions of the model studied53. Although the
decrease was modest, gabapentin and pregabalin
could reverse in part the increase in cortical glutamate
associated with the epileptic state12, 54, 55. The human
and rodent GABA metabolism differ in their response
to antiepileptic drugs23, 56.
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